Wilmington PharmaTech, with locations in Newark, Delaware and Suzhou Jiangsu, China, is expanding and plans to hire as many as 139 new employees and invest $18 million in a new science research and manufacturing facility in Newark, DE.
 
Wilmington PharmaTech, in operation since 2003, is a contract research and manufacturing organization that provides integrated services to pharma and biopharma companies to expedite new product development. One of its main offerings is manufacturing of Active Pharmaceutical Ingredients (API’s) and related materials under cGMP.
 

PharmaTech currently employs 37 full-time staff in the U.S. at several Newark locations, including a 16,000 square foot building at 229A Lake Drive, a 50,000 square foot facility on Sunset Lake Road, and a 40,000 square foot building at Pencader Drive. 
 
“This marks the next wave of growth, positioning Wilmington PharmaTech as the leader in new drug manufacturing in the US,” Said Hui-Yin Harry Li, Ph.D., president and chief executive officer of Wilmington PharmaTech. “This expansion scales up operations and significantly enhances offerings to our clients in API manufacturing and related services. It also expands our portfolio of research, development, and potential commercial API services. PharmaTech’s expansion plans fulfill the commitment to growth and its hallmark reputation for excellence for our employees, customers, partners and our community in the state of Delaware.”